Pulmonary Arterial Hypertension (PAH) Market 2021 with Global Industry Size, SWOT Analysis, Recent Trends, Demand and Share Estimation by 2025 with Top Countries Data

REPORT HIGHLIGHT

The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 5.38 billion by 2017 with growth rate of 5.6%.

Market Dynamics

According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient’s death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.

Download  Sample of This Strategic Report-https://www.kennethresearch.com/sample-request-10293910

The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.

Furthermore, growing awareness coupled with a well-planned reimbursement structure resulted in superlative diagnosis rate for PAH conditions across the globe, driving the industry growth. However, patent expiry of blockbuster therapeutics pulls back the industry growth to some extent. For instance, drugs such as Uptravi (2023), Orenitram (2024), and Opsumit are expired in near future. Additionally, this condition is often not diagnosed in a timely manner owing to its symptoms are subtle, and is confused with many other disease conditions. This fact would, in turn, further reduce the number of patients undergoing PAH treatment, hampering the market growth to some extent.

Drug Class Takeaway

In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.

Global Pulmonary Arterial Hypertension Market, by Drug Class, 2017 vs 2025

Regional Takeaway

Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.

Request For Full Report-https://www.kennethresearch.com/sample-request-10293910

Key Vendor Takeaway

Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as “Tomorrow”) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.’s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2014 & 2016

Base Year – 2017

Estimated Year – 2018

Projected Year – 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY DRUG CLASS

Prostacyclin and Analogs

Soluble Guanylyl Cyclase (SGC) Stimulators

Endothelin receptor antagonist (ERA)

Phosphodiesterase-5

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Name: Kenneth research

Email:sales@kennethresearch.com

Phone: +1 313 462 0609

Comments

Post a Comment

Popular posts from this blog

Regulatory Technology (RegTech) Market 2021 Report On Research Report 2021, Size, CAGR Value, Growth Rate, Latest Trends, Business Investment Plans, SWOT Analysis, Forecast to 2030

  In a recent published report, Kenneth Research has updated the market report for Regulatory Technology (RegTech) Market for 2021 till 2030. Report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In the view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to be regain 25% by the end of 2021- Positive Growth in the economic demand and supply. U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4  billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, pi...
Read more

Unified Threat Management (UTM) Software Market 2021, Research Methodology, Emerging Trends and Forecast 2026 | Says Kenneth Research

  Kenneth Research has published a detailed report on Unified Threat Management (UTM) Software Market, which has been categorized by market size as well as growth indicators and further encompasses detailed market analysis on macro trends and region-wise growth in North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa region. The report also includes the challenges that are affecting the growth of the industry and offer a strategic evaluation that is required to boost the growth of the market over the period of 2021-2026. The Unified Threat Management (UTM) Software Market is expected to grow with a significant CAGR during the forecast period, i.e. 2021-2026, on the back of growing internet penetration around the world along with the rising adoption of smartphones. The statistics by the GSMA Intelligence stated that the total unique mobile subscribers as of May 2020 around the world was 5.24 billion. “Final Report will add the analysis of the impact of...
Read more

Japan Automotive Testing Market Size, Share 2021 | Growing Rapidly with Industry Share, On Going Trends, Future Demand, Recent Developments, Sales & Revenue Value, Industry Expansion Strategies till 2030

  The Japan automotive testing market is estimated to garner a revenue of USD 2072.1 Million by the end of 2028 by growing at a CAGR of 5.5% over the forecast period, i.e., 2021 - 2028. Moreover, in the year 2018, the market in the country generated a revenue of USD 1519.2 Million. The growth of the market can primarily be attributed to the presence of some of the global vehicle manufacturing brands in the country, including brands such as Toyota, Honda, Suzuki, Isuzu, Mazda, Nissan, Subaru, and others, and therefore the rising need amongst these vehicle manufacturers to test their vehicles. Vehicle manufacturers, before launching any product in to the market, often test their vehicles so as to ensure the quality of the vehicle is rightly delivered to its customers. Additionally, with the presence of a prominent automotive industry in the nation, there is a rise in focus on operational excellence of the vehicles. Moreover, growing awareness for vehicle safety and strict regulatory ...
Read more